EP. 2: Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
March 4th 2025Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.
Watch
EP. 4: Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
March 14th 2025Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.
Watch
EP. 6: Overcoming Key Operational Challenges in Integrating Bispecific Therapies
March 21st 2025Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.
Watch
EP. 7: Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology
March 28th 2025Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.
Watch
EP. 8: Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
March 28th 2025Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.
Watch
EP. 9: Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
April 4th 2025Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an effective CRS management protocol as well as best practices for transitions of care between settings when administering and managing bispecifics.
Watch
Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.
Watch